Abstract

The Adverse Outcome Pathway (AOP) concept has recently been proposed to support a paradigm shift in regulatory toxicology testing and risk assessment. This concept is similar to the Mode of Action (MOA), in that it describes a sequence of measurable key events triggered by a molecular initiating event in which a stressor interacts with a biological target. The resulting cascade of key events includes molecular, cellular, structural and functional changes in biological systems, resulting in a measurable adverse outcome. Thereby, an AOP ideally provides information relevant to chemical structure-activity relationships as a basis for predicting effects of structurally similar compounds. AOPs could potentially also form the basis for qualitative and quantitative predictive modeling of the human adverse outcome resulting from molecular initiating or other key events for which higher-throughput testing methods are available or can be developed.A variety of cellular and molecular processes are known to be critical for normal function of the central (CNS) and peripheral nervous systems (PNS). Because of the biological and functional complexity of the CNS and PNS, it has been challenging to establish causative links and quantitative relationships between key events that comprise the pathways leading from chemical exposure to an adverse outcome in the nervous system. Following introduction of the principles of MOA and AOPs, examples of potential or putative adverse outcome pathways specific for developmental or adult neurotoxicity are summarized and aspects of their assessment considered. Their possible application in developing mechanistically informed Integrated Approaches to Testing and Assessment (IATA) is also discussed.

Highlights

  • Modes of Action (MOA) and Adverse Outcome Pathways (AOPs) describe mechanistic knowledge at varying levels of biological organization to facilitate its assimilation, integration and evaluation for research and regulatory applications

  • AOPs describe a sequence of measurable key events (KEs) originating from a molecular initiating event (MIE) resulting in cellular, structural and functional changes and measurable adverse outcomes (AOs) relevant to the human organism and the human population

  • Weight of evidence (WoE) considerations for hypothesized MOAs/AOPs have been developed in this update and more recently evolved as a basis for contributing to the revision of guidance and electronic tools for an international knowledge base of AOPs, which was developed for an initiative of the Organization for Economic Cooperation and Development (OECD)

Read more

Summary

INTRODUCTION

Modes of Action (MOA) and Adverse Outcome Pathways (AOPs) describe mechanistic knowledge at varying levels of biological organization to facilitate its assimilation, integration and evaluation for research and regulatory applications. Recent international developments are anticipated to contribute to increasing collective confidence in applying AOPs for both regulatory risk assessment and research These include an update of the World Health Organization/International Programme on Chemical Safety (IPCS) mode of action/human relevance (MOA/HR) framework. Weight of evidence (WoE) considerations for hypothesized MOAs/AOPs have been developed in this update and more recently evolved as a basis for contributing to the revision of guidance and electronic tools for an international knowledge base of AOPs, which was developed for an initiative of the Organization for Economic Cooperation and Development (OECD) These advances in considering weight of evidence as a basis to increase consistency and confidence in potential applications of AOPs are summarized and illustrated by examples for developmental or adult neurotoxicity. Possible application in developing mechanistically informed Integrated Approaches to Testing and Assessment (IATA) is discussed

The Need for Mechanistically Based Testing and Assessment
Evolution of MOA Analysis
AOPs and Knowledge Base
Interface of MOA Analysis and AOPs
Challenges for developing AOPs relevant to neurotoxicity evaluation
Essentiality of the KE
Essentiality of KE
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call